title: Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome.
abstract: OBJECTIVE
  To report a case of juxtafoveal choroidal neovascularization in a patient with presumed ocular histoplasmosis syndrome (POHS) who was treated with intravitreal injection of bevacizumab (Avastin) as initial treatment.
  
  
  METHODS
  A 23-year-old woman with POHS presented with sudden dimness of vision and metamorphopsia in the right eye. The patient was examined with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT).
  
  
  RESULTS
  Fundus examination, fluorescein angiography, and OCT of the right eye revealed a juxtafoveal choroidal neovascularization. Intravitreal injection of bevacizumab was performed with a postoperative improvement of visual acuity and resolution of the distortion.
  
  
  CONCLUSIONS
  This case report describes a case of juxtafoveal choroidal neovascularization associated with POHS that responded remarkably well to intravitreal injection of bevacizumab.
authors.affiliation: Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Calle Villarroel 170, 08036 Barcelona, Spain. amadan@clinic.ub.es
authors.forename: Alfredo
authors.initials: A
authors.lastname: Adán
authors.forename: Manuel
authors.initials: M
authors.lastname: Navarro
authors.forename: Ricardo P
authors.initials: RP
authors.lastname: Casaroli-Marano
authors.forename: Santiago
authors.initials: S
authors.lastname: Ortiz
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Molina
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D015821:Eye Infections, Fungal / Q000150:complications*; D005260:Female; D005451:Fluorescein Angiography; D006660:Histoplasmosis / Q000150:complications*; D006801:Humans; D007267:Injections; D013577:Syndrome; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body